Efficacy of low-molecular-weight heparin delivery with the Dispatch catheter following balloon angioplasty in the rabbit iliac artery.

Local drug delivery can be achieved with active injection systems or passive contact of a compound with the arterial wall. The Dispatch catheter allows for passive diffusion of drugs from drug compartments while preserving blood flow through the central conduit. The aim of this study was to investigate whether a reduction in neointima formation can be achieved by local delivery of a limited amount of a highly concentrated solution of the low-molecular-weight heparin Reviparin. In 16 New Zealand white rabbits, successful balloon dilatation was performed in both iliac arteries, followed by local delivery of 4 ml Reviparin (1,000 IU/ml). The arteries were harvested at 7, 28, or 56 d following the procedure. The intimal cell layers increased substantially between 7 and 28 d following balloon dilatation with or without local drug delivery. The medial cell layers showed only a little increase. Proliferation of smooth muscle cells reached an early peak after 7 d, with a significantly higher proliferation index following local delivery. The maximum amount of macrophages in the intima and media was detected after 28 d. The lumen area decreased with time and was 0.6 +/- 0.7 mm2 in the local delivery group at 56 d compared with 0.5 +/- 0.5 mm2 in the control group. In conclusion, local delivery of Reviparin with the Dispatch catheter is safe and feasible. However, the infusion of highly concentrated low-molecular-weight heparin over a short period of time did not result in a reduction of neointima formation and restenosis following balloon dilatation in the rabbit iliac artery.

[1]  A. Baumbach,et al.  Porous balloon delivery of low molecular weight heparin in the dog coronary artery. , 1996, European heart journal.

[2]  N. Fineberg,et al.  Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. , 1995, Circulation.

[3]  P. Serruys,et al.  Intracoronary heparin delivery in humans. Acute feasibility and long-term results. , 1995, Circulation.

[4]  P. Yock,et al.  Intramural delivery of agent via a novel drug-delivery sleeve. Histological and functional evaluation. , 1995, Circulation.

[5]  A. Goetz,et al.  A new catheter for prolonged local drug application , 1995, Coronary artery disease.

[6]  R. Califf,et al.  Low Molecular Weight Heparin in Prevention of Restenosis After Angioplasty: Results of Enoxaparin Restenosis (ERA) Trial , 1994, Circulation.

[7]  A. Baumbach,et al.  Accumulation of macrophages in the arterial vessel wall following experimental balloon angioplasty. , 1994, European heart journal.

[8]  R. Virmani,et al.  Feasibility and drug delivery efficiency of a new balloon angioplasty catheter capable of performing simultaneous local drug delivery , 1993, Coronary artery disease.

[9]  C. Lambert,et al.  Local drug delivery catheters: functional comparison of porous and microporous designs , 1993, Coronary artery disease.

[10]  Lippincott Williams Wilkins,et al.  Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angiopla , 1992, Circulation.

[11]  K. Karsch,et al.  Inhibition of Cellular Proliferation After Experimental Balloon Angioplasty by Low‐Molecular‐Weight Heparin , 1992, Circulation.

[12]  E. Nabel,et al.  Site-specific gene expression in vivo by direct gene transfer into the arterial wall. , 1990, Science.

[13]  K. Karsch,et al.  Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. , 1990, Circulation research.

[14]  M. Savage,et al.  A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. , 1990, Circulation.

[15]  S. Thung,et al.  Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. , 1990, Journal of the American College of Cardiology.

[16]  S. Ellis,et al.  Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. , 1989, American heart journal.

[17]  J. Hopper,et al.  Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty. , 1989, Journal of the American College of Cardiology.

[18]  L Schwartz,et al.  Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. , 1988, The New England journal of medicine.